Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$20.77 USD
-0.54 (-2.53%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $20.80 +0.03 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Denali Therapeutics Inc. [DNLI]
Reports for Purchase
Showing records 121 - 140 ( 185 total )
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Consistent CSF Target Engagement Data Might Establish Pipeline Potential Across Multiple Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
The Pubmed Times: Loss of C9orf72 in Microglia Leads to Complement Mediated Neurodegeneration
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
The Pubmed Times - Interplay of Astrocytic APOE4 and Microglial TREM2 in Tau-Mediated Neurodegeneration
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Follow the Biomarkers - DNLI''s Mantra for Drug Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
First, Detailed Look At DNL151 - Looking Ahead To DNL310 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
DNL310 Remains In Focus, But Pipeline Shouldn''t Be Overlooked
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Denali Pushes the Pedal on TV Platform Our Insights on the ATV:TREM2 program; Reit Buy and Raising PT to $95
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
DNL310 Continues Promise As DNLI Provides 12 Week Update at WORLD
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L